πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,444 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11236339

Modulation of GYS1 expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11236338

Antisense-induced exon2 inclusion in acid alpha-glucosidase

Sarepta Therapeutics, Inc. Β· Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11230712

Compounds and methods for reducing SNCA expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11225664

Modulation of angiopoietin-like 3 expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Jan 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11225641

Probiotic Bifidobacterium strain

PrecisionBiotics Group Limited Β· Granted Tue Jan 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11214801

RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11214802

RNAi agents for inhibiting expression of alpha-ENaC and methods of use

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11214803

Modulators of YAP1 expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11208662

RNAi inhibition of alpha-ENaC expression

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11208650

Modulators of IRF5 expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11198876

Compositions and methods for inhibiting expression of TMPRSS6 gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11197837

Methods and compositions for interfering with extraction or conversion of a drug susceptib

Acurx Pharmaceuticals, Inc. Β· Granted Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11193128

Compositions for modulating expression of C9ORF72 antisense transcript

Ionis Pharmaceuticals, Inc. Β· Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11191935

Implant delivery system with hydration promotor capability

Nano Precision Medical, Inc. Β· Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11192903

Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11191761

SOMCL-9112 solid dispersion and preparation method thereof and SOMCL-9112 solid preparatio

Shanghai Acebright Pharmaceuticals Group Co., Ltd. Β· Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11186626

Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop

INTEGRATED BIOTHERAPEUTICS, INC. Β· Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11186822

Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

Precision BioSciences, Inc. Β· Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11180765

Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogeni

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11180562

Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-r

CytomX Therapeutics, Inc. Β· Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11174292

Substitutions-modified prefusion RSV F proteins and their use

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11173118

Emulsion formulations of an NK-1 receptor antagonist and uses thereof

Heron Therapeutics, Inc. Β· Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11162096

Methods for modulating expression of C9ORF72 antisense transcript

The Regents of the University of California Β· Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11155815

Compositions and methods for modulating Tau expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted